Yarrow stock: BB Biotech reports a 0.6 percent position in Yarrow stock

Published on 10/24/2026 at 04:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yarrow raised USD 172.5 million in a public offering on September 14, 2026. Yarrow stock had a 10.6 percent Bellevue stake disclosed October 7, 2026.

Ownership and reporting milestones

BB Biotech reported a 0.6 percent Yarrow position on October 23, 2026.
Second-quarter revenue was USD 0.10 million versus USD 0.20 million expected on August 13, 2026.
Bellevue reported 1,000,000 shares, equal to 10.6 percent of Yarrow, on October 7, 2026.
Yarrow's next earnings date is November 5, 2026.

YARW, US92941V4077, Illustration mit AI erstellt.

Yarrow Bioscience stock (ISIN US92941V4077) featured at 0.6 percent of BB Biotech's portfolio in the investment company's third-quarter report dated October 23, 2026, according to Markets Insider. The disclosure gives Yarrow a fresh portfolio reference while the clinical-stage biotechnology company advances YB-101 for Graves' disease and thyroid eye disease.

Second-quarter revenue stayed limited

Yarrow reported USD 0.10 million in revenue for the second quarter of 2026, versus USD 0.20 million expected, while earnings per share came to minus USD 3.51 against a consensus loss of USD 0.18, MarketBeat reported on September 27, 2026. The figures underline the gap between Yarrow's current operating revenue and the capital required for clinical development.

The company raised USD 172.5 million in a public offering that closed on September 14, 2026. That financing followed pricing of a USD 150.0 million offering on September 10, 2026, according to StockTitan.

What does the ownership data show?

On August 13, 2026, Yarrow reported second-quarter results with USD 0.10 million in revenue; on September 14, 2026, it closed the USD 172.5 million offering, according to StockTitan. On October 23, 2026, BB Biotech disclosed a 0.6 percent Yarrow position, making the portfolio allocation the latest dated item in the chronology.

Ownership filing sets a clear marker

Bellevue Group AG reported beneficial ownership of 1,000,000 Yarrow shares, equal to 10.6 percent of the class, in a filing dated October 7, 2026. The percentage was based on 9,437,693 shares outstanding after the September offering, StockTitan reported.

The next substantiated reporting date is November 5, 2026, according to Quanteia. The event should provide the next dated test of revenue, cash use and progress around YB-101.

Capital and clinical progress

Yarrow's reported market capitalization was USD 186.1 million as of October 15, 2026. Its second-quarter operating cash flow was negative USD 1.99 million, while cash and equivalents stood at USD 22.93 million on June 30, 2026. The combination of a large September financing and limited quarterly revenue leaves clinical execution as the central company-specific issue.